← Browse by Condition
Medical Condition
diffuse midline glioma h3 k27m mutant
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2, Phase 1
NCT06161974 Phase 2
Recruiting
Study of Olutasidenib and Temozolomide in HGG
Enrollment
60 pts
Location
United States, Austr...
Sponsor
Rigel Pharmaceuticals
NCT05762419 Phase 1
Recruiting
FUS Etoposide for DMG
Enrollment
10 pts
Location
United States
Sponsor
Columbia University